| Bioactivity | WJ460 is a potent myoferlin (MYOF) inhibitor, which interacts directly with MYOF and exerts anti-metastatic activity in the nanomolar range in breast cancer cells[1]. | ||||||||||||
| Target | MYOF | ||||||||||||
| Invitro | WJ460 blocks breast cancer cell invasion with IC50 values of 43.37 ± 3.42 nM in MDA-MB-231 and 36.40 ± 4.51 nM in BT549 cells. WJ460 treatment remarkably inhibits MDA-MB-231 and BT549 cell invasion through Collagen I in a dose-dependent manner[1]. | ||||||||||||
| In Vivo | WJ460 inhibits breast tumor growth, angiogenesis, and spontaneous metastasis in a spontaneous metastasis model[1]. | ||||||||||||
| Name | WJ460 | ||||||||||||
| CAS | 1415251-36-3 | ||||||||||||
| Formula | C27H28N2O3S | ||||||||||||
| Molar Mass | 460.59 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Zhang T, et al. A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer. Nat Commun. 2018 Sep 13;9(1):3726. |